BridgeMD
Optimizing the time of day of influenza vaccine administration in adults aged 60-85 years: A randomized controlled trial
EU CTIS ID: 2024-513558-30-00
What this study is testing
Determine the effect of the time of day of influenza vaccine administration on influenza vaccine strain-specific serum antibody titers 28 days (+/- 3 days) after vaccination in adults aged 60-85 years.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged 60-85 years at the time of inclusion.
- Willing and able to come to the vaccination location at a randomly assigned timeslot.
- Available for the follow-up period of 6 months.
- Have provided written informed consent.
You likely can't join if
- Known or suspected allergy to any of the vaccine components or having experienced a previous severe adverse reaction to any vaccine.
- Known to have an increased susceptibility to bleeding (bleeding diathesis), and are therefore not suitable for intramuscular vaccination.
- Present evidence of serious diseases demanding either regular use of oral immunosuppressive medical treatment, like corticosteroids, three months prior to study enrolment, or demanding acute use of high dose oral immunosuppressives two weeks prior study to study enrolment.
- Receipt of an organ- or bone marrow transplant
- Receipt of chemotherapy in the previous year.
- Receipt of blood products or immunoglobulins, within 3 months before study entry.
See the full eligibility criteria
- Aged 60-85 years at the time of inclusion.
- Willing and able to come to the vaccination location at a randomly assigned timeslot.
- Available for the follow-up period of 6 months.
- Have provided written informed consent.
- Known or suspected allergy to any of the vaccine components or having experienced a previous severe adverse reaction to any vaccine.
- Known to have an increased susceptibility to bleeding (bleeding diathesis), and are therefore not suitable for intramuscular vaccination.
- Present evidence of serious diseases demanding either regular use of oral immunosuppressive medical treatment, like corticosteroids, three months prior to study enrolment, or demanding acute use of high dose oral immunosuppressives two weeks prior study to study enrolment.
- Receipt of an organ- or bone marrow transplant
- Receipt of chemotherapy in the previous year.
- Receipt of blood products or immunoglobulins, within 3 months before study entry.
- Known or suspected immunodeficiency, auto-immune disease, any type of cancer.
- Known to be positive for human immunodeficiency virus, and/or hepatitis C virus and/or hepatitis B virus.
- Receipt of any vaccine(s), including the COVID-19 vaccine, less than two weeks prior to or within one month after baseline.
- Receipt of influenza 2024/2025-season vaccine prior to or within one month after baseline.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.